tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

SKYE Stock Latest News

Buy Rating for Skye Bioscience: Nimacimab’s Potential in Obesity Treatment Market
RatingsBuy Rating for Skye Bioscience: Nimacimab’s Potential in Obesity Treatment Market
2d ago
SKYE
Skye Bioscience initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Skye Bioscience initiated with a Buy at H.C. Wainwright
4d ago
SKYE
Skye Bioscience presents Phase 1b data from nimacimab study
PremiumThe Fly
Skye Bioscience presents Phase 1b data from nimacimab study
15d ago
SKYE
Skye Bioscience’s Nimacimab: Promising Phase IIa Trial Results and Buy Recommendation
PremiumRatings
Skye Bioscience’s Nimacimab: Promising Phase IIa Trial Results and Buy Recommendation
15d ago
SKYE
Skye Bioscience’s Transformative Potential in Obesity Treatment: A Buy Recommendation by Andy Hsieh
PremiumRatings
Skye Bioscience’s Transformative Potential in Obesity Treatment: A Buy Recommendation by Andy Hsieh
21d ago
SKYE
Skye Bioscience reports results from two preclinical DIO studies on nimacimab
PremiumThe FlySkye Bioscience reports results from two preclinical DIO studies on nimacimab
30d ago
SKYE
Skye Bioscience completes 26-week treatment phase in Phase 2a CBeyond study
Premium
The Fly
Skye Bioscience completes 26-week treatment phase in Phase 2a CBeyond study
1M ago
SKYE
Skye Bioscience to host KOL event on CBeyond Phase 2a clinical data readout
Premium
The Fly
Skye Bioscience to host KOL event on CBeyond Phase 2a clinical data readout
1M ago
SKYE
Evercore starts Skye Bioscience at Outperform on nimacimab potential
PremiumThe Fly
Evercore starts Skye Bioscience at Outperform on nimacimab potential
2M ago
SKYE
Skye Bioscience initiated with an Outperform at Evercore ISI
PremiumThe Fly
Skye Bioscience initiated with an Outperform at Evercore ISI
2M ago
SKYE
Skye Bioscience Earnings Call: Positive Outlook Amid Challenges
PremiumCompany Announcements
Skye Bioscience Earnings Call: Positive Outlook Amid Challenges
2M ago
SKYE
Skye Bioscience Releases Q2 2025 Financial Results
PremiumCompany Announcements
Skye Bioscience Releases Q2 2025 Financial Results
2M ago
SKYE
Skye Bioscience debuts ‘Anatomy of Progress’ nimacimab development update series
PremiumThe FlySkye Bioscience debuts ‘Anatomy of Progress’ nimacimab development update series
3M ago
SKYE
Skye Bioscience participates in panel at Evercore obesity event
Premium
The Fly
Skye Bioscience participates in panel at Evercore obesity event
3M ago
SKYE
Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks
Premium
Stock Analysis & Ideas
Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks
3M ago
PYPD
SKYE
Skye Bioscience to present expanded preclinical CB1 antibody data
PremiumThe Fly
Skye Bioscience to present expanded preclinical CB1 antibody data
4M ago
SKYE
Skye Bioscience Holds 2025 Annual Stockholders Meeting
PremiumCompany Announcements
Skye Bioscience Holds 2025 Annual Stockholders Meeting
4M ago
8K
SKYE
Strategic Collaboration and Promising Therapeutic Approaches Drive Buy Rating for Skye Bioscience
PremiumRatings
Strategic Collaboration and Promising Therapeutic Approaches Drive Buy Rating for Skye Bioscience
5M ago
SKYE
Skye Bioscience’s Promising Peripheral CB1R Obesity Treatment Drives Buy Rating
PremiumRatings
Skye Bioscience’s Promising Peripheral CB1R Obesity Treatment Drives Buy Rating
5M ago
SKYE
Skye Bioscience presents PK, PD model on CB1 inhibitors
PremiumThe FlySkye Bioscience presents PK, PD model on CB1 inhibitors
5M ago
SKYE
Skye Bioscience price target lowered to $17 from $21 at Oppenheimer
Premium
The Fly
Skye Bioscience price target lowered to $17 from $21 at Oppenheimer
5M ago
SKYE
Promising Developments and Strong Clinical Engagement Lead to Buy Rating for Skye Bioscience
Premium
Ratings
Promising Developments and Strong Clinical Engagement Lead to Buy Rating for Skye Bioscience
5M ago
SKYE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >